{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"0.0","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"CYCLE 1 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"147.0","upperLimit":"447.0","value":"218.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"CYCLE 1 DAY 1, END OF INFUSION"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"231.0","upperLimit":"556.0","value":"376.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"CYCLE 1 DAY 1, 2 HOURS"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"547.0","upperLimit":"1670.0","value":"750.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"CYCLE 1 DAY 1, 24 HOURS"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"218.0","upperLimit":"1780.0","value":"549.50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"CYCLE 1 DAY 4"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"67.1","upperLimit":"264.0","value":"170.90"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"CYCLE 1 DAY 8"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"CYCLE 1 DAY 22"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"0.0","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"title":"CYCLE 2 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"394.0","upperLimit":"716.0","value":"555.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"title":"CYCLE 2 DAY 1, END OF INFUSION"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"CYCLE 4 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"469.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"CYCLE 4 DAY 1, END OF INFUSION"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"END OF TREATMENT"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"description":"Blood samples were collected for PK analysis of belantamab mafodotin cys-mcMMAF when administered intravenously in combination with dostarlimab.","dispersionType":"Full Range","groups":[{"description":"Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received 1.9 milligram (mg)/kilogram (kg) belantamab mafodotin intravenous (IV) infusion as powder for solution once every 3 weeks (Q3W) infused over 30- 60 minutes on day 1 of 21-day cycles in combination with 500 mg dostarlimab as a 30-minute IV infusion 1 hour after belantamab mafodotin end of infusion (EOI) on day 1 of 21-day cycles (Q3W).","id":"OG000","title":"1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab"}],"paramType":"MEDIAN","populationDescription":"Pharmacokinetic population. Only those participants with data available at the specified data points were analyzed.","reportingStatus":"POSTED","timeFrame":"Predose, end of infusion (EOI), 2, and 24 hours postdose on Cycle 1 Day 1, and at Cycle 1 Day 4, Day 8, Day 22, Predose and EOI on Cycle 2 Day 1, Cycle 4 Day 1, and at end of treatment (approximately 153 weeks)","title":"DE Phase: Belantamab Mafodotin Concentrations for Plasma Cys-mcMMAF","type":"SECONDARY","unitOfMeasure":"ng/mL"}